GlobeNewsWire
05 Jan 2026, 12:30 UTC · 35w ago
Verdict
Headline takes no side. We score ALT +1.00 across four claims.
Our read: bullish.
ALT score
+1.00
More positive than 99% of ticker scores this week
Price reaction
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen
What the story claims
4 claims · scored −1 bearish … +1 bullish
The FDA has granted Breakthrough Therapy Designation (BTD) to Altimmune's pemvidutide for the treatment of MASH.
More positive than 98% of claims this week
Altimmune and the FDA have reached alignment on parameters for the registrational Phase 3 trial of pemvidutide.
More positive than 91% of claims this week
Continue reading
5 related stories
Search tags
Phase 2b trial data showed statistically significant MASH resolution without worsening fibrosis and sustained weight loss at 48 weeks.
More positive than 85% of claims this week
The upcoming Phase 3 trial will use biopsy-based endpoints to seek potential accelerated approval.
More positive than 77% of claims this week
Which stocks this story touches
More positive than 99% of ticker scores this week
The company received FDA Breakthrough Therapy Designation for pemvidutide and aligned on Phase 3 trial parameters.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Price reaction
Expected +1.00Actual −6.8%
Price is moving against the score
173 sessions since publication. $3.27 vs $3.51 close before publication (Jan 2). Not market-adjusted.
ALT chart →
